• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - neutrophils
Tag:

neutrophils

Health

High immune cell ratios may predict future Alzheimer’s disease risk

by Chief Editor April 21, 2026
written by Chief Editor

The New Frontier of Early Dementia Detection

For decades, the challenge with Alzheimer’s disease and related dementias has been the “silent window”—the period where the brain is changing, but the patient shows no outward signs of cognitive impairment. A groundbreaking shift is occurring in how we identify this window, moving away from waiting for memory loss and toward analyzing the body’s immune response.

Recent large-scale research led by NYU Langone Health has highlighted a potent biomarker: the neutrophil to lymphocyte ratio (NLR). By analyzing data from nearly 400,000 patients across the Veterans Health Administration and NYU Langone hospitals, researchers found that elevated neutrophil metrics are associated with an increased risk of future dementia long before symptoms manifest.

What Exactly is the Neutrophil to Lymphocyte Ratio (NLR)?

Neutrophils are white blood cells that act as the immune system’s “first responders.” They typically surge in number during inflammation or infection. When clinicians perform a standard complete blood cell count, they can easily determine the ratio of these neutrophils to lymphocytes (another type of white blood cell).

View this post on Instagram about Alzheimer, Neutrophils
From Instagram — related to Alzheimer, Neutrophils

While a high NLR is commonly used to diagnose acute infections, its application as a predictive tool for brain health is a new development. The data suggests that when this ratio is elevated in adults aged 55 and older, it may signal a higher short-term and long-term risk of developing Alzheimer’s.

Did you understand? Neutrophils are constantly being recycled and only live for a few days. This makes them hard to study because they require fresh blood samples and cannot be stored or frozen like other cell types.

How Inflammation Signals Future Cognitive Decline

The connection between blood metrics and brain health lies in inflammation. While neutrophils are essential for healing wounds, they can also cause tissue damage at the vascular level. This specific type of damage is frequently seen in patients with Alzheimer’s and dementia.

The evidence is mounting that neutrophils aren’t just markers of the disease, but may be active participants. Research in mice has shown that neutrophils can actually accelerate the progression of Alzheimer’s. Neutrophil inflammation has been identified within the brain pathology of human Alzheimer’s patients.

There is also the possibility that the aging process itself disrupts how the body recycles neutrophils, leading to a buildup that causes systemic tissue damage.

Demographic Disparities in Risk

Not all populations react to these immune markers in the same way. The research indicates that the risk associated with elevated NLR values is more pronounced in certain groups:

Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM
  • Women: The risk was found to be higher for women across both evaluated health systems.
  • Hispanic Patients: A higher risk was also tied to NLR values in Hispanic patients.

Experts note that it is not yet clear if these disparities are driven by genetic factors or social determinants, such as unequal access to healthcare.

Pro Tip: An elevated NLR result is likely not sufficient to predict dementia on its own. However, when combined with other known risk factors, it can serve as a “gateway” to prompt more comprehensive testing.

Future Trends: From Markers to Medicine

The trajectory of dementia care is moving toward “gateway diagnostic tools.” Instead of expensive or invasive tests for everyone, clinicians may use the NLR as an initial screen to identify high-risk individuals who require more in-depth interventions.

The next phase of research, currently being conducted at the Vascular and Immune Dysfunction in Aging and Alzheimer’s Disease (VIDA) lab, involves combining NLR measurements with advanced imaging techniques, including:

  • PET Scans: To visualize amyloid plaques and tau tangles.
  • Diffusion MRI: To examine the structural integrity of the brain.
  • Cognitive Testing: To correlate immune activity with actual mental performance.

If scientists can prove that neutrophils actively drive the progression of dementia, these cells could grow a primary therapeutic target. This would shift the treatment paradigm from managing symptoms to blocking the immune-driven damage before it begins.

For more information on how inflammation affects the body, you can explore resources on inflammation and health or review the full study in the journal Alzheimer’s & Dementia.

Frequently Asked Questions

Can a simple blood test diagnose Alzheimer’s?

No. A high neutrophil to lymphocyte ratio (NLR) is a risk marker, not a definitive diagnosis. It identifies people who may be at higher risk and should undergo more comprehensive testing.

Frequently Asked Questions
Alzheimer Neutrophils Dementia

Why are neutrophils linked to brain health?

Neutrophils can cause vascular tissue damage. Because this type of damage is seen in Alzheimer’s pathology, researchers believe neutrophil-driven inflammation may contribute to cognitive decline.

At what age does NLR screening become relevant for dementia risk?

The recent large-scale study focused on patients who were at least 55 years classic.

What is the difference between a marker and a cause?

A marker (like NLR) is a sign that something is happening in the body. A cause is the actual mechanism driving the disease. Researchers are currently investigating if neutrophils are simply markers or if they are actively causing the disease to progress.


Join the Conversation: Do you feel routine immune screening should become part of standard senior health check-ups? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in neurological health.

April 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

EMA Recommends Romvimza for TGCT Treatment

by Chief Editor July 28, 2025
written by Chief Editor

New Horizons in TGCT Treatment: What the EMA Approval of Romvimza Signals

The recent recommendation by the European Medicines Agency (EMA) to approve Romvimza (vimseltinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) marks a significant leap forward. As a healthcare journalist specializing in rare diseases, I’ve been closely following the developments in this area, and the potential impact of this new treatment is substantial. But what does this mean for patients, and what can we anticipate in the future?

Understanding the Impact of Romvimza

TGCT, a rare condition characterized by the overgrowth of synovial tissue, causes debilitating pain, swelling, and limited mobility. For those patients where surgery isn’t an option, treatment choices have been scarce. Romvimza, a switch-control TKI targeting the colony-stimulating factor 1 receptor (CSF1R), aims to address this unmet need. In the phase 3 MOTION study, the results were striking: a 40% objective response rate with vimseltinib compared to 0% with placebo. This translates to real relief for patients grappling with this challenging disease.

Did you know? TGCT affects approximately 43 people per million. Early diagnosis and targeted treatment, like Romvimza, can significantly improve patient outcomes and quality of life.

Looking Ahead: Emerging Trends in TGCT Management

The approval of Romvimza is not just a win for current patients; it’s also a signal of progress. We’re witnessing an era of targeted therapies that specifically address the underlying mechanisms of diseases like TGCT. Here’s what to watch for:

  • Personalized Medicine: As we learn more about the genetic and molecular profiles of TGCT, expect to see treatments tailored to individual patient needs. This might involve identifying biomarkers that predict response to certain therapies, optimizing treatment strategies and reducing the risk of side effects.
  • Combination Therapies: Researchers are exploring combining therapies to enhance efficacy. For instance, combining Romvimza with other agents that target different aspects of the tumor microenvironment could lead to more comprehensive disease control.
  • Novel Drug Targets: Beyond CSF1R inhibition, scientists are investigating other potential drug targets within the signaling pathways involved in TGCT. Clinical trials are already underway exploring alternative pathways.
  • Advances in Diagnostics: The development of more sensitive and specific diagnostic tools, including advanced imaging techniques and liquid biopsies, is crucial for early detection and monitoring treatment response. This will help clinicians make more informed decisions.

For more information on TGCT, explore resources from the National Organization for Rare Disorders (NORD).

Patient-Centric Care: The Future of Treatment

The shift toward patient-centric care is another important trend. This involves a holistic approach that considers not only the biological aspects of the disease but also the patient’s overall well-being. Factors like pain management, physical therapy, and psychological support play a vital role in improving quality of life.

Pro tip: Always consult with your doctor and consider participating in clinical trials to stay informed about the latest advances in TGCT treatment and explore additional options.

FAQ: Frequently Asked Questions About TGCT and Romvimza

What is the main benefit of Romvimza?

It provides a new treatment option for adults with symptomatic TGCT who are not candidates for surgery, significantly reducing tumor growth and improving symptoms.

What are the common side effects of Romvimza?

Common side effects include elevated liver enzymes, periorbital edema, increased cholesterol, rash, and hypertension.

How does Romvimza work?

It works by inhibiting CSF1R, a key driver of TGCT pathology, thus controlling tumor growth.

Where can I find more detailed information about Romvimza?

Detailed information will be available on the EMA website after the marketing authorization is granted.

As a specialist in the pharmaceutical sector, I believe that this represents a major development in the TGCT landscape. The focus is no longer solely on palliative care, but on offering patients a chance to manage and significantly improve the quality of their life.

What are your thoughts on the future of TGCT treatment? Share your comments and insights below!

July 28, 2025 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Israel’s E1 Plan Threatens Palestinian Contiguity: Al-Eizariya at Risk

    May 11, 2026
  • Survey: 30% of Americans Believe Trump Assassination Attempts Were Staged

    May 11, 2026
  • Marvel’s Doomsday Savior

    May 11, 2026
  • Sinner vs Popyrin: Live Streaming & Preview of Rome Masters

    May 11, 2026
  • Huawei Unveils Watch Fit 5 & FreeClip 2: New Features & Payments

    May 11, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World